Endothelium-independent vasodilatory effect of Sailuotong (SLT) on rat isolated tail artery by Yeon, Seungyeon (S33272) et al.
Research Article
Endothelium-Independent Vasodilatory Effect of Sailuotong
(SLT) on Rat Isolated Tail Artery
S. Y. Yeon ,1 S.W. Seto ,1,2 G. H. H. Chan,3M. Low ,1 H. Kiat ,4,5,6 N.Wang,1,7 J. Liu,1,8
and D. Chang 1
1NICM Health Research Institute, Western Sydney University, Penrith, NSW 2751, Australia
2Department of Applied Biology and Chemical Technology, 'e Hong Kong Polytechnic University, Hung Hom, Kowloon,
Hong Kong SAR, China
3Hong Kong Community College, 'e Hong Kong Polytechnic University, Hung Hom, Kowloon, Hong Kong
4Faculty of Medicine, University of New South Wales, Kensington, NSW 2052, Australia
5School of Medicine, Western Sydney University, Penrith, NSW 2571, Australia
6Faculty of Medicine and Health Sciences, Macquarie University, Sydney, NSW 2113, Australia
7Key Laboratory of Chinese Medicinal Formula of Anhui Province, Anhui University of Chinese Medicine, Hefei 230012, China
8Xiyuan Hospital, China Academy of Chinese Medical Sciences, Beijing, China
Correspondence should be addressed to S. W. Seto; saiwang.seto@polyu.edu.hk
Received 15 June 2020; Revised 21 August 2020; Accepted 7 September 2020; Published 22 September 2020
Academic Editor: Silvia Wein
Copyright © 2020 S. Y. Yeon et al. (is is an open access article distributed under the Creative Commons Attribution License,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Background. Sailuotong (SLT) is a standardized three-herb formulation consisting of extracts of Panax ginseng,Ginkgo biloba, and
Crocus sativus for the treatment of vascular dementia (VaD). Although SLT has been shown to increase cerebral blood flow, the
direct effects of SLTon vascular reactivity have not been explored. (is study aims to examine the vasodilatory effects of SLTand
the underlying mechanisms in rat isolated tail artery.Methods. Male (250–300 g) Wistar Kyoto (WKY) rat tail artery was isolated
for isometric tension measurement. (e effects of SLTon the influx of calcium through the cell membrane calcium channels were
determined in Ca2+-free solution experiments. Results. SLT (0.1–5,000 μg/ml) caused a concentration-dependent relaxation in rat
isolated tail artery precontracted by phenylephrine. In the contraction experiments, SLT (500, 1,000, and 5,000 μg/mL) sig-
nificantly inhibited phenylephrine (0.001 to 10 μM)- and KCl (10–80mM)-induced contraction, in a concentration-dependent
manner. In Ca2+-free solution, SLT (500, 1,000, and 5,000 μg/mL) markedly suppressed Ca2+-induced (0.001–3mM) vaso-
constriction in a concentration-dependent manner in both phenylephrine (10 μM) or KCl (80mM) stimulated tail arteries. L-type
calcium channel blocker nifedipine (10 μM) inhibited PE-induced contraction. Furthermore, SLT significantly reduced phen-
ylephrine-induced transient vasoconstriction in the rat isolated tail artery. Conclusion. SLT induces relaxation of rat isolated tail
artery through endothelium-independent mechanisms. (e SLT-induced vasodilatation appeared to be jointly meditated by
blockages of extracellular Ca2+ influx via receptor-gated and voltage-gated Ca2+ channels and inhibition of the release of Ca2+
from the sarcoplasmic reticulum.
1. Background
Cerebrovascular diseases (CVDs), including ischemic stroke
and vascular dementia (VaD), are among themajor causes of
morbidity and mortality in developing and developed
countries [1]. CVDs are strongly associated with a number of
risk factors, such as hypertension, obesity, aging, diabetes,
and hypercholesterolemia [2]. Altered vascular reactivity,
such as impaired vasodilatation or enhanced vasoconstric-
tion, has been considered one of the common characteristics
associated with these risk factors [3–5], directly contributing
to the development and progression of CVD. For example,
impaired vascular relaxation has been shown to play a role in
the development of VaD in deoxycorticosterone acetate
(DOCA) salt-induced hypertensive rats [6]. Similarly, im-
paired carotid artery relaxation has been suggested as a
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contributor to stroke and dementia in aged mice [7].
(erefore, interventions that can induce vasodilation or
suppress vasoconstriction could be useful in reducing the
progression of CVD.
Sailuotong (SLT) is a standardized three-herb formula
Chinese herbal medicine designed for the management of
VaD associated with ischemic stroke [8, 9]. (e SLTformula
consists of standard extracts of specific dosages of Panax
ginseng C. A. Meyer (ginseng), Gingko biloba L. (ginkgo),
and Crocus sativus L. (saffron). (e chemical profile and
ratio of the three herbal extracts had been determined and
studied in detail previously [10, 11].(e cognitive enhancing
effect of SLT has been demonstrated in both preclinical and
clinical studies. In a chronic cerebral hypoperfusion model
induced by bilateral common carotid artery ligation in rats,
eight-week treatment of SLT significantly suppressed
hypoperfusion-induced cognitive impairments, and this
change is associated with reduction of activity of cholin-
esterase and increased acetylcholine (ACh) levels and su-
peroxide dismutase (SOD) activity the brain tissue [8]. Our
previous work also showed that SLT protected cultured
human vascular endothelial cells against hydrogen peroxide-
induce injury via increase in SOD activity [12]. (e potential
beneficial effects of SLT for VaD were demonstrated in two
separate phase II randomized, double-blinded, placebo-
controlled clinical studies. In these studies, treatment with
SLT was shown to significantly improve cognitive function
and cerebral blood flow to the inferior frontal and anterior
temporal lobes in patients with VaD [11, 13].
Reports from animal and clinical studies have indicated
that the clinically beneficial effect of SLT is, at least, partially
associated with an increase in cerebral blood flow [14, 15].
However, the underlying mechanism(s) associated with
these SLT-mediated cerebral blood flow increase remain to
be determined. In this study, we hypothesised that SLT has
direct modulatory effects in vascular reactivity. (erefore,
this study was aimed to evaluate the vascular effects and the
underlying mechanisms of SLT using rat isolated tail artery.
2. Methods
2.1.Chemical andDrugs. SLTextracts were provided in-kind
by the Shineway Pharmaceutical Group (Shijiazhuang,
China). Acetylcholine (ACh), phenylephrine, calcium
chloride (CaCl2), tetraethylammonium (TEA), clotrimazole,
glibenclamide, potassium chloride (KCl), ethylene glycol-
bis(β-aminoethyl ether)-N,N,N′,N′-tetraacetic acid (EGTA),
l-N-nitro arginine methyl ester (L-NAME), and nifedipine
were purchased from Sigma-Aldrich (St Louis, MO, USA).
All the other reagents were of analytical grade.
2.2. High-Performance 'in-Layer Chromatography (HPLC)
Analysis of the SLT Formula. HPLC-PDA was employed to
profile the phytochemical composition of the SLT extract
used in the study. (e HPLC-PDA analysis was performed
on a Prominence-I LC-2030 3D Plus Shimadzu HPLC
system controlled by Lab Solutions software (Shimadzu,
Australia). Separation was achieved using a Shimadzu Shim-
pack GIST (Shimadzu, Australia) reverse phase C18 column
(4.6×150mm I.D., 5 μm) maintained at 40°C.
(e SLT extract was dissolved by sonication in 30%
aqueous acetonitrile for 30min at 5mg/ml. Individual so-
lutions of standards, crocin, ginsenoside Re, ginsenoside
Rg1, ginsenoside Rd, quercetin, kaempferol, and iso-
rhamnetin were prepared to 1mg/10ml in 30% aqueous
acetonitrile for identification and combined for analysis.(e
sample and mixed standard were syringe-filtered with
0.45 μm PTFE.
(e SLT HPLC-PDA profiles were generated by 20 μl
injection. (e mobile phase consisted of 0.1% (v/v) aqueous
formic acid (mobile phase A) and 0.1% (v/v) formic acid in
acetonitrile (mobile phase B). (e gradient program was
10% B for 1min with a linear increase, to 45% B at 45min,
and then, a wash and re-equilibration.(emobile phase flow
rate was maintained at 1.1ml/min. (e PDA was set to
acquire absorbance data from 190 to 800 nm.
2.3. Animals. A total of forty 12-week-old, male Wistar
Kyoto (WKY) rats weighting 200–250 g were obtained from
the Animal Resource Centre (Canning Vale, Western
Australia). All experimental animals were housed under a
12:12 hour light-dark cycle (relative humidity: 50–60%;
temperature: 22± 1°C) and were given standard chow and
water ad libitum throughout the experimental period. On
the day of experiment, the rats were sacrificed by CO2 as-
phyxiation, and vascular preparations were isolated under a
dissection microscope. All animal protocols conformed to
the Guide for the Care and Use of Laboratory Animals by the
Australian Code of Practice for the Care and Use of Animals
for Scientific Purpose [16]. Institutional ethics approval
(Approval number: A12041) was obtained from Western
Sydney University prior to commencement of the study.
2.4. Isometric Tension Measurement. Isometric force mea-
surements and experimental protocols were performed on
tail artery isolated from the WKY rats as described previ-
ously with slight modifications [5, 17].(e isometric force of
the arterial ring segments was measured using a multiwire
myograph system (Model 620M; Danish Myo Technology,
DMT, Denmark). During the isometric tension measure-
ment, the chambers of the myograph were filled with
Krebs–Henseleit solution (mmol/L: NaCl 118.0, KCl 4.7,
K3PO4 1.2, MgSO4 1.2, NaHCO3 25.0, CaCl2 1.8, glucose
11.0), unless stated otherwise. (e Krebs–Henseleit solution
were prepared and used as follows: All solutions were
warmed to 37°C and bubbled with carbogen (95%O2 and 5%
CO2) before they were added to the myograph chamber.
Each chamber containing 5ml of Krebs buffered solution
was bubbled with 95% O2 and 5% CO2 and maintained at a
pH of 7.4 at 37°C throughout the experiment. Arterial rings
(1.5–2.0mm length) were mounted in the organ chambers,
and normalized passive resting force and the corresponding
diameter were determined for each preparation from its own
length-pressure curve and stretched to their optimal lumen
diameter (i.e.,∼90% of the diameter which is equivalent to a
transmural pressure of 100mm Hg). (e rings were, then,
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left for a stabilization period of about 30 minutes until a
stable base line tone was obtained before beginning of the
experiment. (e presence of the endothelium was tested
with acetylcholine (1 μM) after preconstriction with phen-
ylephrine (PE) (1 μM). Tissues which showed a relaxation to
acetylcholine of less than 60% of the phenylephrine con-
traction were not considered with intact endothelium and,
therefore, not employed in this study. Responses were
recorded using computerized data acquisition and recording
software.
2.5. Experimental Protocols of Vascular Tension Studies
2.5.1. Protocol 1: Vasodilatory Effect of the SLT Extract in Rat
Isolated Tail Arteries. (e acute and direct vasodilatory
effect of SLT was evaluated on rat isolated tail artery. PE
(1 μM) was applied to induce a steady contraction. When the
contraction reached a plateau, the SLT extract (0.1–5000 μg/
ml) was added cumulatively to the isolated tail artery rings
with or without the presence of L-NAME (20 μM) to obtain a
concentration-response curve. (e relaxation effect was
calculated as the percentage of the contraction in response to
PE.
2.5.2. Protocol 2: Effects of Potassium Channel Blockers on
SLT-Induced Vasodilation in Rat Isolated Tail Arteries.
Rat isolated tail arteries were preincubated with various K+
channel blockers: (1) nonselective K+ channel blocker, tet-
raethylammonium (TEA, 1mM); (2) selective ATP-sensitive
K+ channel (KATP) blocker, glibenclamide (3 μM), and (3)
Ca2+-dependent K+ channel (KCa) blockers, clotrimazole
(5 μM). Each blocker was allowed to incubate with the
preparation for 30min before the construction of a con-
centration-response curve.
2.5.3. Protocol 3: Calcium-Induced Vasoconstriction in Rat
Isolated Tail Arteries. (e effect of SLT on calcium influx
induced by two different agents was evaluated. (e prepa-
rations were initially contracted with either KCl (80mM) or
PE (10 μM) to determine maximum contraction of each
preparation in normal Krebs solution. (e preparations
were washed with a calcium-free solution (identical con-
centration of EGTA substituted for Ca2+ in a normal Krebs
solution) until fully relaxed. To exhaust the intracellular
calcium storage, the preparations were stimulated with ei-
ther PE (10 μM) or KCl (80mM) repeatedly, with calcium-
free solution wash in between, until any contractile response
disappeared. (e preparations were, then, incubated with
SLT at various concentrations (500, 1,000, and 5,000 μg/ml)
for 30min. After incubation, a single dose of the contractile
agent (either KCl (80mM) or PE (10 μM) was added to the
chamber, and calcium (0.001–3mM)-induced contraction
concentration response curves were constructed.
2.5.4. Protocol 4: Phenylephrine- and Potassium Chloride-
(KCl-) Induced Vasoconstriction in Rat Isolated Tail Arteries.
In order to assess the effects of SLT on the contraction
induced by phenylephrine and potassium chloride (KCl),
concentration-response curves of PE and KCl were con-
structed with or without the presence of SLT at various
dosages (500, 1,000, and 5,000 μg/ml). (e arterial prepa-
rations were allowed to preincubate with SLT (0, 500, 1,000,
and 5,000 μg/ml) for 30 minutes’ prior the construction of
the PE or KCl-induced vasoconstriction concentration-re-
sponse curve.
2.5.5. Protocol 5: Role of Intracellular Calcium-Induced
Vasoconstriction in Rat Isolated Tail Arteries. To clarify the
role of intracellular Ca2+ release from the sarcoplasmic
reticulum (SR) in the relaxant effect of SLT, the isolated
tail artery rings were exposed to a Ca2+-free solution for
15 minutes before the application of 1 μM of PE to induce
the first transient contraction (Con 1). (e rings were,
then, washed with a normal Krebs solution for three times
and incubated in the normal Krebs solution for 45
minutes to allow refill of the intracellular Ca2+ storage.
After the 45-minute incubation, the medium was rapidly
replaced with a Ca2+-free solution and allowed to incubate
for 15 minutes. (e second contraction (Con 2) was in-
duced by 1 μM of PE with or with the presence of SLT
(500, 1,000, or 5,000 μg/ml). (e ratio of Con 2 to Con 1
was calculated.
2.6. Statistical Analysis. Data are expressed as mean-
s± S.E.M., and n denotes the number of replications for each
data point. Relaxation was expressed as the percentage of the
contraction elicited by phenylephrine or KCl. Statistical
comparisons were performed using the t-test or two-way
analysis of variance (ANOVA), where appropriate. Differ-
ences were considered to be statistically significant at
P< 0.05. All statistical analyses were performed using
GraphPad Prism 5 software (GraphPad Software, Inc., USA).
3. Results
3.1. High-Performance 'in-Layer Chromatography (HPLC)
Analysis of the SLT Extract. (e active ingredients and
contents in SLT have been reported in details previously
[10, 11]. Six major bioactive compounds were analyzed using
HPLC. Similar to these studies, our results showed that all
these major bioactive compounds, including ginsenosides
Rg1, ginsenosides Re, ginsenosides Rb1, quercetin, iso-
rhamnetin, and crocin, are present in the SLT extract
(Figure 1). (e chromatogram is visualized at different
wavelengths corresponding to the optimal wavelength to
detect the relevant group of markers. SLT is reported to
contain ginsengs as ginsenosides Rg1 (2.4mg/capsule),
ginsenosides Re (1.6mg/capsule), and ginsenosides Rb1
(4.49mg/capsule). (e ginsenosides were confirmed to be
present in similar concentrations by matching retention
time and the UV spectrum to the reference standards as
shown in Figure 1 at 203 nm.(e peak size is not reflective of
abundance as the different ginsenosides have unique molar
absorptivity. SLT is reported to contain Ginkgo biloba, with
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markers quercetin (2.71mg/capsule) and isorhamnetin
(1.55mg/capsule). (ese were identified in the SLT extract
used in this study as shown in Figure 1 at 370 nm. SLT is
reported to contain saffron, with the marker crocin (1.7mg/
capsule). Crocin was identified in the SLTextract used in this
study as shown in Figure 1 at 440 nm. (e HPLC analysis of
the SLT extract supplied by Shineway was consistent with
other reports [10, 11].
3.2. Vasodilatory Effects of the SLT Extract in Rat Isolated Tail
Arteries. SLT (0.1–5,000 μg/ml) caused a relaxation in the
PE (1 μM)-preconstricted rat isolated tail artery in a con-
centration-dependent manner. (e relaxation was initiated
at 100 μg/ml and achieved 80.104± 9.80% at 5,000 μg/ml
(n� 6) (Figure 2). Preincubation of the isolated tail artery
with L-NAME (20 μM) did not significantly alter the SLT-
induced relaxation (n� 6) (Figure 2).
3.3. Effects of Potassium Channel Blockers on SLT-Induced
Vasodilatation in Rat Isolated Tail Arteries. Opening of
potassium channels plays an important role in vasodilata-
tion. We examined the involvement of potassium channels
on the SLT-induced relaxation in the rat isolated tail arteries.
Tetraethylammonium (TEA, a nonselective potassium
channel blocker) (1mM), glibenclamide (Glib, an ATP-
sensitive potassium channel blocker) (3 μM), and clo-
trimazole (KCa, a calcium-activated potassium channel
blocker) (5 μM) were tested. As shown in Figure 2, pre-
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Figure 1: HPLC chromatograms of the SLT extract. (e chromatogram (a) at 203 nm (pink) shows the ginsenosides Rg1, ginsenosides Re,



















Figure 2: Cumulative concentration-response of the SLT extract
(0.1–5,000 μg/ml) on phenylephrine (1 μM)-preconstricted rat
isolated tail artery with (●) or without (○) the presence of L-NAME
(20 μM). Values are expressed as mean± SEM (n� 6).
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significantly alter the SLT-induced vasodilatation in PE
(1 μM)-preconstricted rat isolated tail artery (n� 5-6)
(Figure 3).
3.4. Effects of the SLT Extract on Calcium-Induced Vaso-
constriction in Rat Isolated Tail Arteries Stimulated by
Phenylephrine or KCl. (e effect of the SLT extract on
calcium-influx-induced vasoconstriction on rat isolated tail
arteries was assessed with two vasocontractile stimulants
(phenylephrine and KCl) by reintroducing calcium
(0.001–3mM) into the calcium-free buffer. In the phenyl-
ephrine (10 μM)-stimulated tail arteries, cumulative ad-
ministration of calcium chloride (0.001–3mM) induced a
vasoconstriction in a concentration-dependent manner,
with 29.167± 7.23% contraction observed at 3mM (n� 5).
Preincubation of the SLT extract (500, 1,000, and 5,000 μg/
ml) dose-dependently suppressed the calcium-induced va-
soconstriction in the phenylephrine (10 μM)-isolated tail
arteries. SLTat 5,000 μg/ml and nifedipine (10 μM)markedly
suppressed the calcium-induced vasoconstriction
(Figure 4(a)).
Similarly, in the KCl (80mM)-stimulated tail arteries,
cumulative administration of calcium chloride
(0.001–3mM) induced a vasoconstriction in the tail artery in
a concentration-dependent manner, with 75.460± 14.52%
contraction observed at 3mM (n� 6). Preincubation of the
SLT extract at 1,000 and 5,000 μg/ml, but not 500 μg/ml,
markedly inhibited the calcium-induced vasoconstriction in
the KCl (80mM)-stimulated isolated tail arteries. SLT at
5,000 μg/ml abolished the calcium-induced vasoconstriction
(n� 6) (P< 0.001) (Figure 4(b)).
3.5. Effects of the SLT Extract on Phenylephrine- and KCl-
Induced Vasoconstriction in Rat Isolated Tail Arteries. (e
effects of the SLT extract (500, 1,000, and 5,000 μg/ml) on
phenylephrine-induced vasoconstriction in rat isolated tail
arteries were evaluated. Cumulative addition of phenyl-
ephrine (0.0001–10 μM) caused a vasoconstriction in the tail
arteries in a concentration-dependent manner. Pre-
incubation of the SLT extract at 1,000 and 5,000 μg/ml, but
not 500 μg/ml, significantly suppressed the phenylephrine-
induced vasoconstriction in the isolated tail arteries (n� 5)
(P< 0.001). Nifedipine (10 μM) markedly reduced the PE-
induced vasoconstriction (Figure 5(a)).(e vasoconstriction
caused by phenylephrine at 10 μMwas markedly suppressed
by 67.58%with the presence of the SLTextract at 5,000 μg/ml
(control: 16.44± 2.46mN vs. SLT: 5.33± 1.02mN) (P< 0.05)
(n� 5) (Figure 5(b)).
(e effects of the SLT extract (500, 1,000, and 5,000 μg/
ml) on KCl-induced vasoconstriction in rat isolated tail
arteries were evaluated. Cumulative addition of KCl
(10–80mM) caused a vasoconstriction in the tail arteries in a
concentration-dependent manner. Preincubation of the SLT
extract at 500, 1,000, and 5,000 μg/ml significantly sup-
pressed the KCl-induced vasoconstriction in the isolated tail
arteries in a dose-dependent manner. (n� 3) (P< 0.001)
(Figure 5(c)). (e vasoconstriction caused by 80mM was
abolished with the presence of the SLTextract at 5,000 μg/ml
(control: 7.90± 1.75mN vs. SLT: 0.54± 0.31mN) (P< 0.05)
(n� 3) (Figure 5(d)).
3.6. Effect of SLT on Intracellular Calcium Release.
Phenylephrine (PE) (1 μM) caused a transient contraction in
the Ca2+-free solution through a release of intracellular Ca2+
from the sarcoplasmic reticulum. A second transient con-
traction was induced with or without the presence of SLT
(500, 1,000, and 5,000 μg/ml). SLT significantly suppressed
the PE-induced transient contraction ratio (Con 2/Con 1) at
5,000 μg/ml (CLT: 39.12± 6.28 vs. SLT 5,000 μg/ml:
6.86± 1.52) (P< 0.05) (n� 6) (Figure 6).
4. Discussion
Vascular dementia (VaD) is considered to be caused by
chronic cerebral ischemia which induces neuronal damage,
resulting in a decline in cognitive function eventually. While
the development and progression of cognitive impairment
and VaD are certainly multifactorial, it has been suggested
that cerebrovascular dysfunction leads to reduction of ce-
rebral blood flow which is closely associated with cognitive
impairment in diabetes [18, 19]. Sailuotong (SLT) is a
standardized three-herb formula designed for the man-
agement of VaD. Although data from animal and clinical
studies have indicated that the clinically beneficial effect of
SLT is closely associated with an increase in cerebral blood
flow [11–13], the acute and direct modulatory effects and the
underlying mechanisms of actions of SLT in vascular re-
activity have not been studied. Results from the current work
provide evidence that the SLT extract induces vascular re-
laxation in rat isolated tail arteries. Furthermore, our results


















Figure 3: Effects of potassium channel blockers on SLT extract-
induced relaxation on phenylephrine (1 μM)-preconstricted rat
isolated tail artery. Tail arteries were preincubated with either
vehicle control (○), tetrethyl-ammonium (TEA, a nonselective
potassium channel blocker) (1mM) (●), glibenclaminde (Glib, an
ATP-sensitive potassium channel blocker) (3 μM) (■), or clo-
trimazole (KCa, a calcium-activated potassium channel blocker)
(5 μM) (▲) for 30 minutes before construction of the concentra-
tion-response curve. Values are expressed as mean± SEM (n� 5-6).











































Figure 4: (a) Effect of the vehicle control (○), SLTextract (500 (●), 1000 (■), or 5000 (▲) μg/ml), or nifedipine (10 μM) (◆) on Ca2+-induced
vasoconstriction in phenylephrine (PE) (10 μM)-stimulated rat isolated tail arteries. Values are expressed as mean± SEM (∗∗∗P< 0.001 vs
Control) (n� 5). (b) Effect of the vehicle control (○) and SLT extract (500 (●), 1,000 (■), or 5,000 (▲) μg/ml) on Ca2+-induced vaso-
constriction in potassium chloride (KCl) (80mM)-stimulated rat isolated tail arteries. Values are expressed as mean± SEM (∗∗P< 0.01 vs.





















































































Figure 5: (a) Effect of the vehicle control (○), SLT extract (500 (●), 1000 (■), or 5000 (▲) μg/ml), or nifedipine (10 μM) (◆) on
phenylephrine-induced vasoconstriction in rat isolated tail arteries. Values are expressed as mean± SEM (∗∗∗P< 0.001 vs. control) (n� 5).
(b) Isometric tension change of phenylephrine (10 μM)-induced vasoconstriction in rat isolated tail arteries with (closed bar) or without
(open bar) the presence of the SLT extract (5000 μg/ml). Values are expressed as mean± SEM (∗∗P< 0.01) (n� 8). (c) Effect of the vehicle
control (○) or SLT extract (500 (●), 1,000 (■), or 5,000 (▲) μg/ml) on potassium chloride (KCl) (80mM)-induced vasoconstriction in rat
isolated tail arteries. Values are expressed as mean± SEM (∗P< 0.05; ∗∗P< 0.01; ∗∗∗P< 0.001 vs. control) (n� 3). (d) Isometric tension
change of KCl (80mM)-induced vasoconstriction in rat isolated tail arteries with (closed bar) or without (open bar) the presence of the SLT
extract (5,000 μg/ml). Values are expressed as mean± SEM (∗∗P< 0.01) (n� 3).
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endothelium-independent mechanisms including inhibition
of extracellular Ca2+ influx and release of Ca2+ storage from
the sarcoplasmic reticulum.
(e individual herb extracts of SLT have been shown to
induce vasodilatation via endothelium-mediated mecha-
nisms [20]. For example, crocetin, a carotenoid derived from
saffron, has been shown to exert vasomodulatory effects via
an endothelium-dependent mechanism [21]. Similarly,
previous studies have demonstrated that ginseng produces
its vasodilatory effect through eNOS activation in the en-
dothelium [22, 23]. In contrast, our results revealed that
inhibition of the endothelium by L-NAME failed to suppress
the SLT-induced vasodilatation, indicating that the SLT-
induced relaxation is largely mediated by an endothelium-
independent mechanism. (is relaxation was most likely
caused by the complex constituents within the SLT extract
which acted directly on the vascular smooth muscle cell
(VSMC). For instance, the Ginkgo biloba extract (GBE) has
been shown to induce vasodilation viamultiple mechanisms,
including inhibition of calcium influx through the L-type
calcium channel and the activation of NO release in the rat
isolated aorta [24]. Indeed, it has been shown that, while all
the Ginkgo extract constituents, including bilobalide,
ginkgolide A, ginkgolide B, ginkgolide C, quercetin, and
rutin, have vasodilating action, each of them can contribute
to GBE-induced vasorelaxation with different mechanisms
and signaling pathways [25].
Since our results indicate that the SLT-induced relaxa-
tion was not mediated via the endothelium, other endo-
thelium-independent mechanisms were considered.
Vascular tone and reactivity regulation are primarily con-
trolled by the changes of intracellular calcium within the
vascular smooth muscle cell (VSMC) [26]. A number of
calcium channels and mechanisms are responsible for the
increase of the intracellular calcium level in VSMC [27–30],
and many herbs and their isolated compounds have been
shown to induce vasodilatation via inhibition of calcium
influx in the VSMC [24]. For instance, the Ginkgo biloba
extract has been shown to induce aortic relaxation via in-
hibition of calcium influx through the calcium channel [24].
Similarly, ginsenoside Rg(3), an active ingredient of Panax
ginseng, has been shown to inhibit the L-type calcium
channel in Xenopus oocytes in a dose- and voltage-depen-
dent manner [31]. In the current study, reintroduction of
calcium to phenylephrine- or KCl-stimulated isolated tail
artery bathed in a calcium-free solution caused contractions
in a concentration-dependent manner. (ese results clearly
demonstrated the role of calcium influx in vasoconstriction
in response to both receptor-mediated (i.e., phenylephrine)
and voltage-mediated (KCl) stimulations. SLT dose-de-
pendently inhibited the calcium-influx-induced vessel
contraction to both phenylephrine- and KCl-stimulated tail
arteries, suggesting SLT was likely to inhibit both receptor-
and voltage-mediated calcium influx. In line with this, the
ability of SLT to suppress both phenylephrine- and KCl-
mediated responses were clearly demonstrated in the
phenylephrine- and KCl-induced vasoconstriction experi-
ments, where SLTmarkedly suppressed the vasoconstriction
caused by both agents. (erefore, our results suggested that
SLT suppressed calcium influx by inhibition of both the
voltage-operated calcium channel (VOCC) and receptor-
operated calcium channel (ROCC).
Although the effects of SLT on intracellular calcium
storage regulation in VSMC have not been reported pre-
viously, the individual components of SLT have been shown
to suppress increase of the intracellular calcium level via
inhibition of both influxes of extracellular Ca2+ and release
of intracellular Ca2+ storage. In our study, SLT inhibited the
PE-induced transient contraction in the isolated tail artery,
indicating that SLT suppressed the vasoconstriction via
inhibition of the release of Ca2+ from the sarcoplasmic
reticulum. Similar to our study, ginsenoside-Rd, a main
active constituent of Panax ginseng, has been shown to
suppress phenylephrine-induced contraction in rat isolated
aorta via inhibition of both receptor- and store-operated
calcium channels in VSMC [22]. Yang et al. [32] have shown
that the antiplatelet and antithrombosis properties of saffron
were mediated by a mechanism involving inhibition of
calciummobilization via reducing both intracellular calcium
release and extracellular calcium influx [32].
Many herbal medicines have been shown to produce
their cardiovascular protective effects via the opening of
potassium channels in VSMCs, such as the ATP-sensitive
potassium channel (KATP) and calcium-activated potassium
channel (KCa) [33, 34]. For example, Li et al. [35] showed
that ginsenosides (GS), an extract of Panax ginseng, induced
aortic relaxation and is, at least, partly mediated by the
opening of the KCa channel in the VSMC [35]. Similarly,
activation of the potassium channel has also been demon-
strated in ginsenoside Rg3-mediated endothelium-depen-
dent relaxation in rat isolated aorta [36]. (e Ginkgo extract
has been shown to relax smooth muscle cell via a TEA-
sensitive (a nonselective potassium channel blocker)
mechanism [37] and opening of the KCa channel [38], while




















Figure 6: Effect of the SLTextract (500, 1,000, and 5,000 μg/ml) on
phenylephrine (10 μM)-induced transient vasoconstriction in rat
isolated tail arteries. Con2/Con1 (%) refers to the ratio of the
second contraction to the first contraction. Values are expressed as
mean± SEM (∗P< 0.05 vs control) (n� 6).
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via inhibition of calcium influx [24, 39] and activation of
eNOS [40]. In this study, preincubation of TEA (a nonse-
lective potassium channel blocker), glibenclamide (an ATP-
sensitive potassium channel blocker), and clotrimazole (a
calcium-activated potassium channel blocker) did not have
any effects on the SLT-induced relaxation in the rat isolated
tail artery, suggesting that the relaxation was independent of
potassium channels opening. Although the effects of the
individual components of SLT on the potassium channel
have been reported previously [36], it is not uncommon that
Chinese herbal medicine can induce relaxation independent
of potassium channel activation. For example, the Danshen
aqueous extract and its active component, Salvianolic acid B,
have been shown to produce their vasorelaxant effect in-
dependent from potassium channel opening [41].
(ere are three limitations in the current study. First of
all, although numerous studies have demonstrated that the
reactivity profile of the rat tail artery resembles the human
peripheral arteries [42–44] and have been used as an ex vivo
model of resistance artery which can be extrapolated to
human peripheral vascular disease [45], quantitative mea-
surement of cerebrovascular reactivity should be employed
in the future study. In addition, while our current work
showed that acute SLT administration did not induce en-
dothelium-dependent vasodilatation in the vessels isolated
from a healthy animal, previous work from our group has
demonstrated that SLT protected the cultured human en-
dothelial cell from oxidative injury [12], indicating that the
endotheliummodulatory effects of SLTcan only be observed
under diseased conditions. Hence, endothelial effects of SLT
in disease models should be studied in the future. Finally,
while the active components of SLT have been shown to be
absorbed into systematic circulation [46], any effects me-
diated by the metabolites of SLTmay be overlooked by the ex
vivo model used in the current study. A detailed metab-
olomics study is required to identify and explore the possible
contribution of metabolites of SLT on vasculature.
5. Conclusions
In conclusion, we demonstrated that acute administration of
the SLT extract induced vasodilatation in rat isolated tail
artery. SLT-induced vasodilatation appeared to be princi-
pally mediated via endothelium-independent mechanisms,
including blockage of extracellular Ca2+ influx and inhibi-
tion of release of Ca2+ from the sarcoplasmic reticulum.
Results from this work provide direct evidence to explain the



















KATP: ATP-sensitive potassium channel
KCa: Calcium-dependent potassium channel
SR: Sarcoplasmic reticulum
VSMC: Vascular smooth muscle cell
VOCC: Voltage-operate calcium channel
ROCC: Receptor-operate calcium channel.
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